SCHEMBL2397530

SCHEMBL2397530

NC(=O)Cc1ccccc1-c1ccc(F)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
ATR Q13535 1/20 0.39
ALDH1A1 P00352 2/20 0.37
LMNA P02545 3/20 0.35
RAB9A P51151 2/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
CYP2C19 P33261 1/20 0.35
ICMT O60725 2/20 0.34
P2RX7 Q99572 1/20 0.34
MAOB P27338 1/20 0.34
PARP15 Q460N3 1/20 0.34
PARP14 Q460N5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395880 0.89 ALDH1A1 (0.41) ATRALDH1A1LMNARAB9AMAPT
SCHEMBL27325719 0.84 MPO (0.43) CTSLCTSSCTSKALDH1A1LMNA
SCHEMBL2391854 0.83 ALDH1A1 (0.45) ATRALDH1A1LMNARAB9AMAPT
SCHEMBL2393300 0.80 GRM2 (0.50) ALDH1A1CYP2C19ICMTL3MBTL1
SCHEMBL2393136 0.79 SLC9A1 (0.42) MAPTSMN1; SMN2CES2CES1ICMT
SCHEMBL9890790 0.79 PKM (0.40) ALDH1A1LMNARAB9AMAPTNPC1
SCHEMBL9890745 0.79 CHRM1 (0.43) ALDH1A1LMNARAB9AMAPTNPC1
SCHEMBL9890738 0.79 ALDH1A1 (0.41) ATRALDH1A1LMNARAB9AMAPT
SCHEMBL2393938 0.78 KCNA5 (0.37) ATRALDH1A1LMNARAB9ACES2
SCHEMBL2397118 0.78 CHRM3 (0.44) LMNASMN1; SMN2CYP2C19ICMTCXCL8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CTSL 4275/4885CTSS 3584/4885CTSK 4415/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CTSL 4275/4885CTSS 3584/4885CTSK 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.